Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ( 18 F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer-Reference-Cited by-同舟云学术

Multisite Experience of the Safety, Detection Rate and Diagnostic Performance of Fluciclovine ( 18 F) Positron Emission Tomography/Computerized Tomography Imaging in the Staging of Biochemically Recurrent Prostate Cancer

Published:2017-03 Issue:3 Part 1 Volume:197 Page:676-683
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Bach-Gansmo Tore¹,Nanni Cristina²,Nieh Peter T.³,Zanoni Lucia²,Bogsrud Tronde Velde¹,Sletten Heidi¹,Korsan Katrine Andersen¹,Kieboom J.⁴,Tade Funmilayo I.⁵,Odewole Oluwaseun⁵,Chau Albert⁶,Ward Penelope⁶,Goodman Mark M.⁵,Fanti Stefano²,Schuster David M.⁵,Willoch Frode⁴⁷

Affiliation:

1. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway

2. Nuclear Medicine, Azienda ospedaliero-universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy

3. Department of Urology, Emory University, Atlanta, Georgia

4. Department of Nuclear Medicine and Radiology, Aleris Healthcare, Oslo, Norway

5. Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia

6. Blue Earth Diagnostics, Oxford, United Kingdom

7. Institute of Basic Medical Sciences, Faculty of Medicine, University of Oslo, Oslo, Norway

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference28 articles.

1. American Cancer Society: Cancer Facts & Figures 2016. Available at http://www.cancer.org/research/cancerfactsstatistics. Accessed April 14, 2016.

2. Guideline for the management of clinically localized prostate cancer;Thompson;J Urol,2007

3. Current controversies in the management of biochemical failure in prostate cancer;Bruce;Clin Adv Hematol Oncol,2012

4. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results;Roehl;J Urol,2004

5. Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy;Simmons;Eur Urol,2007

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world evidence of ¹⁸F‐fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System;The Prostate;2024-07-19

2. Prostate cancer: nuclear medicine imaging in the biochemical recurrence and in oligometastatic disease;The Quarterly Journal of Nuclear Medicine and Molecular Imaging;2024-06

3. Evaluating appropriateness of 18F-fluciclovine PET/CT relative to standard of care imaging guidelines and the impact of ADT on positivity: a prospective study in 62 Veterans Administration patients at a single institution;Nuclear Medicine Communications;2024-03-22

4. 18F-Fluciclovine;Radiopharmaceuticals;2024

5. Diagnostic Advances: Innovative Techniques and Biomarkers for Prostate Cancer Diagnosis;Transforming Prostate Cancer Care;2024